Verastem's VS-7375 Shows Promising Early Data in KRAS G12D-Mutated Tumors — Verastem, Inc.

Event summary

VS-7375 demonstrated clinical activity across multiple dose levels and tumor types in the TARGET-D 101 Phase 1/2 trial, including metastatic pancreatic ductal carcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small cell lung cancer (NSCLC).
93% of heavily pretreated mPDAC patients achieved greater than 50% reduction in the tumor marker CA19-9 at the 900 mg QD dose level.
Verastem plans to meet with the FDA before the end of 2026 to review Phase 3 pivotal trial designs for first-line treatments in mPDAC, mCRC, and advanced NSCLC.

The big picture

Verastem's VS-7375 is part of a broader industry push to develop targeted therapies for KRAS-mutated cancers, which have historically been difficult to treat. The favorable safety profile and early signs of efficacy position VS-7375 as a potential best-in-class oral KRAS G12D inhibitor, with strategic implications for Verastem's pipeline and competitive landscape in oncology.

What we're watching

Clinical Efficacy: How the emerging clinical data for VS-7375 will impact its competitive positioning against other KRAS G12D inhibitors in development.
Regulatory Pathway: Whether Verastem can secure accelerated approval pathways based on the Phase 2 data, potentially expediting market entry.
Combination Strategies: The pace at which Verastem advances combination therapies with anti-EGFR agents and standard-of-care chemotherapies across different tumor types.